

1. [Drug cos face five-fold hike in regulatory fees](#)

– Times of India  
Pharmaceutical companies may have to shell out more to do business in India. The government has proposed an over five-fold hike in regulatory fees for testing, manufacturing and selling medicines in the country, a move that is likely to impact both domestic as well as multinational pharmaceutical companies operating here.

1. [Drug cos face five-fold hike in regulatory fees](#) – Times of India
2. [Generic drugs fuel pharma sector growth](#) – The Hindu
3. [Government plans Rs 500 crore pharma technology upgradation fund](#) – Economic Times
4. [‘Without good lab practices, drug discoveries to remain non-starters’](#) – The Hindu
5. [Outlook 2016: Five things to look out for in healthcare](#) – VC Circle

2. [Generic drugs fuel pharma sector growth](#)

– The Hindu

India’s pharmaceutical sector is expected to grow at a rate of 14 per cent per annum for the next few years and its size is expected to grow from Rs. 2.24 lakh crore to Rs. 3.17 lakh crore in the next few years, said G.J. Samathanam, former advisor, Department of Science and Technology, Government of India.

The size of the domestic market was around Rs. 66,000 crore and the country was third largest in the world in terms of volume. But it was only 10th in terms of value though it was meeting 10 per cent of global production, he said.

3. [Government plans Rs 500 crore pharma technology upgradation fund](#)

– Economic Times  
DoP is also contemplating to launch a scheme for giving financial assistance in form of soft loans or interest subsidies to select manufacturing facilities

Government is planning to set up a Rs 500-crore pharma technology upgradation fund which will facilitate cheaper loans to entities looking to upgrade their manufacturing facilities.

Besides this, the Department of Pharmaceuticals is already working on a proposal to establish a venture capital fund with a same corpus to provide cheaper loans to small and marginal companies planning to set up new units.

Both these proposals are under consideration to rejuvenate the domestic pharma sector and make medicines more affordable, a senior official told PTI.

Also appeared in [Mint](#), [Financial Express](#), [DNA](#) and [NDTV](#)

4. [‘Without good lab practices, drug discoveries to remain non-starters’](#)

– The Hindu  
India’s quest for global footprint in drug discoveries is bound to fail if there is no emphasis on adhering to international Good Laboratory Practices (GLP), warned G.J. Samathanam, Director of Research and former Advisor and Head, Technology Development & Transfer Division of DST, Government of India.

He was participating in a session on Discovery and Development of Novel Drugs, Make in India — Challenges and Avenues at the Indian Science Congress here on Tuesday.

5. [Outlook 2016: Five things to look out for in healthcare](#) – VC Circle

Coming on the back of what was a record year for private investments and equally busy year with bold overseas bets by Indian drugmakers, the healthcare sector is poised for another year of hectic activity.

Be it the expansion of the pool of public-listed healthcare firms, government policies that could redefine future growth of the sector and breakouts from firms in emerging sub segments of the business, 2016 will be crucial for investors as well as businesses in the sector.